Navigation Links
DMAA to Develop Disease Management Standards by December

WASHINGTON - The Disease Management Association of America (DMAA) has announced the launch of a programme that aims to uniformly measure and evaluate "outcomes in disease and care management programs."

"This certainly stands among // the disease management community's most significant research efforts to date,” Don Fetterolf, MD, chair of the DMAA Quality and Research Committee said. "Reaching consensus on a relevant and scientifically valid standard for evaluating clinical and financial outcomes is vital to the continued strong growth of disease and care management." Dr. Fetterolf will be in charge of the standards development project, which intends to present concrete results by December at the DMAA's 2006 Disease Management Leadership Forum in Denver in the first week of that month. "Our members clearly understand the potential of this project to greatly expand acceptance of disease management by all payers, public and private," said Dr. Fetterolf, Corporate Vice President, Strategic Initiatives, for Matria Healthcare Inc. Initially the group will collect data on how other organization collate their d\own data on disease outcomes. "The DMAA recognized that a gap exists in our understanding of best practices for evaluating disease and care management programs," DMAA Executive Director Tracey Moorhead said. "Our experience shows disease management works, but lack of agreement on how to measure that success has hampered our ability to convince skeptics."

The Disease Management Association of America is a non-profit, voluntary membership association representing all stakeholders in the disease management industry through public and private advocacy targeting the health care industry, government agencies, employers and the general public in an effort to educate them on the important role disease management and care coordination programs play in improving healthcare quality and outcomes for persons with chronic conditions.

Fore more in
'"/>




Page: 1 2

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Risk Of Developing Arthritis
4. Developing HIV fighter
5. Missing Protein In Cancer Development
6. Tomatoes Might Inhibit the Development Of Prostate Cancer
7. Antibiotics Found To Increase The Risk Of Developing Breast Cancer
8. The Effectiveness Of Cancer Drug In Women At Risk Of Developing Cancer
9. Men Who at Risk Of Developing Prostate Cancer
10. Identifying The Risks Of Developing Schizophrenia
11. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
Post Your Comments:
Breaking Medicine News(10 mins):Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:NICE guidelines ration affordable osteoporosis drugs 2Health News:NICE guidelines ration affordable osteoporosis drugs 3Health News:Menopause Often Means Worsening Cholesterol 2Health News:Menopause Often Means Worsening Cholesterol 3Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 3Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 4Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 5Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 6Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 7Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 8Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 9Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 10Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 11Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 12Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 13Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 14Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 15Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 16Health News:New Board Gains Control of U.S. Shanghai Chemical Corporation 2
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2PRA International Experts Present a Session at the 8th Annual Partnerships in Clinical Trials 2009 5873 1PRA International Experts Present a Session at the 8th Annual Partnerships in Clinical Trials 2009 5873 2China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 5870 1China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 5870 2China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 5870 3China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 5870 4Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 5867 1Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 5867 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 5867 3